We've just hit our goal! What an incredible push from our investors, so far. Truly a humbling and exciting result. Now that we're over the line, it's time for the final push. If you're still deciding, now's the time to jump in the water with us! Let's work together to build a better future for our reefs for future generations to enjoy! 🌊

We've broken $210,000 thanks to 106 investors, so far! ​I know many of you care deeply about the environment, and specifically our oceans. This is truly the LAST CHANCE to not just support a great cause, but to actually become a shareholder in a company working to make a massive, scalable impact in the $1.5T Blue Economy. ​The campaign closes tonight at 7:00 PM AWST and they are SO close to hitting their target. If you've been sitting on the fence, please check out the post below. This is your chance to own a piece of a business that is genuinely creating change. ​Let's get them over the line! 🚀🌊

Our raise is now in its final stage and closes at 10 pm tonight - Thursday the 11th of December. If you have been following our progress, this is a good moment to take a closer look at what BioAnalytics is building. Sleep apnoea affects around 8 percent of adults, yet about 40 percent of people cannot tolerate existing therapies. Our device addresses this unmet need with a simpler, patented, low-cost approach supported by published evidence, regulatory approval for the core therapeutic device, and a clear pathway to an independent 20–30 patient clinical trial. We have also added electronics and data capability so the device becomes part of the digital health ecosystem, providing vital patient feedback and enabling remote clinical monitoring. We are focused on creating a high-quality medtech asset backed by strong intellectual property, long-term users of the device, and a well-defined commercialisation pathway. Further information, including our trial data and detailed strategy, is available on the offer page. Thank you to everyone who has supported us so far.

In under 2 minutes: an expert explains BioAnalytics’ new sleep apnoea treatment Our window to invest closes today - please join us

Just 24 hours remaining to invest in Reef Craft! ⏳ A huge thank you to all the incredible people who have invested so far - we are so close to our goal! 🚨 FINAL DEADLINE: Reef Craft's crowdfunding campaign closes tomorrow, December 11th, at 7:00 pm AWST (10:00 pm AEDT). If you've been meaning to invest, or know anyone who cares deeply about our oceans and would be interested in jumping on board, NOW is the time! Every dollar counts and every individual sends a powerful message to industry and decision-makers: we want to preserve our reefs. Even a small investment makes a big difference to our campaign and our mission. Don't let this final opportunity slip away! Head to the "Invest" page, to get started. We look forward to welcoming you aboard.

If you invest in BioAnalytics it's reassuring to know Under Birchal’s crowd-sourced funding (CSF) model, investors acquire and hold fully paid ordinary shares directly in the issuing company. Birchal DOES NOT use a nominee, custodian or bare trust structure to bundle investors’ interests. Investors who invest through Birchal: Are issued fully paid ordinary shares directly by BioAnalytics Holdings. Hold full legal and equitable title to those shares upon issue. Appear individually on the BioAnalytics share register and cap table as shareholders. Exercise the rights associated with ordinary shares, including voting rights, dividend rights and rights on exit (subject only to the company’s constitution and Corporations Act requirements). Birchal’s role is strictly that of a licensed CSF intermediary, facilitating the offer and application process in accordance with Part 6D.3A of the Corporations Act 2001. Birchal does not hold shares on trust, does not interpose itself between the investor and the company, and does not aggregate holdings under a single nominee entity.

In less than 2 minutes, hear about our strategy

How lucky are we to have the support of ex- Federal Aviation Administration vertiport specialist, Robert Bassey as Skyportz® prepares the Aeroberm™ patent for entry to the USA market? If we get the product right under the FAA requirements this will speed up entry to all emerging markets. The issues we are addressing around downwash/outwash safety and noise will be universal, wherever anyone tries to establish a network of urban landing sites. We are supported by a great technical team developing our IP with peer reviewed science. Thank you Justin Leontini and Andrew Che from Swinburne University of Technology, Esmaeel Masoudi and Mahdi Azarpeyvand from University of Bristol, Simon McCarthy from Systemised Design Group Pty Ltd, Hamed Ghajarnia from CRINNAC and of course our patent attorney who is is busily protecting all this research, Nicola Maxwell from Jones Maxwell Smith & Davis (JMSD)

When people hear about our device, the next question is usually the same: Why add electronics and an app? In sleep apnea, what matters is not what we think is happening, but what is actually happening, night after night. Electronic monitoring lets us see breathing patterns and how often events occur. That means we can diagnose accurately, tune the therapy for each patient, and prove with data that it is working. It also gives clinicians something they have never really had with oral devices, which is continuous, objective feedback instead of guesswork. That is a big shift. Instead of relying on how a patient feels or remembers their sleep, we can show what really happened. We have built an electronics platform that streams sleep data via Bluetooth to an app. That turns the device from a piece of hardware into part of the wider digital health ecosystem. At scale, that data becomes a strategic asset for larger health and technology companies. We now hold a patent for this, including in the US. This is very deliberate. Digital health is one of the fastest-growing parts of healthcare. Globally, digital health is already a multi-hundred-billion dollar market and is expected to more than double over the next decade. Within that, remote monitoring of patients at home is growing rapidly, as health systems and insurers look for better outcomes at a lower cost. In sleep medicine, we have already seen what this looks like. The big players have moved from selling just devices to building connected platforms. Their most valuable asset is not only the hardware, it is the continuous flow of real-world sleep data sitting behind it. That is what allows them to prove outcomes, keep patients engaged, and build long-term relationships with clinicians and payers. BioAnalytics sits on that same strategic axis, but in an unserved part of the market (40% of all people with sleep apnea or $3 billion PA). We are taking an approved, well-understood treatment concept, adding high-quality monitoring, and doing it in a way that fits naturally into the digital health world. For a company with a strategic interest, that combination of device plus data is what creates value. At the same time, there is a large market for a simpler version of the device without electronics, and I have spoken about that separately in my secondary markets update. That version opens up opportunities in areas like snoring and medical procedures, where price and simplicity matter more than data. So from an investor’s perspective, the electronics are not a gadget we bolted on at the end. They are central to the clinical value, they are central to how we differentiate, and they are central to how we fit into the broader digital health and medtech landscape. That is why we invested in building an electronics platform, why we protected it with a patent (one of five), and why we see it as central to creating value for shareholders through the right strategic partner.

Why is BioAnalytics interesting - Its business model!